239 related articles for article (PubMed ID: 34536299)
1. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
2. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the role of Wnt biology in cancer.
Mirabelli CK; Nusse R; Tuveson DA; Williams BO
Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289213
[TBL] [Abstract][Full Text] [Related]
4. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
5. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
Shah K; Panchal S; Patel B
Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
[TBL] [Abstract][Full Text] [Related]
6. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
7. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
Mukherjee N; Panda CK
Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
[TBL] [Abstract][Full Text] [Related]
8. Molecular strategies for modulating Wnt signaling.
Gustafson CT; Mamo T; Maran A; Yaszemski MJ
Front Biosci (Landmark Ed); 2017 Jan; 22(1):137-156. PubMed ID: 27814607
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
Cheng X; Xu X; Chen D; Zhao F; Wang W
Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Liu Z; Wang P; Wold EA; Song Q; Zhao C; Wang C; Zhou J
J Med Chem; 2021 Apr; 64(8):4257-4288. PubMed ID: 33822624
[TBL] [Abstract][Full Text] [Related]
11. The involvement of noncanonical Wnt signaling in cancers.
Chen Y; Chen Z; Tang Y; Xiao Q
Biomed Pharmacother; 2021 Jan; 133():110946. PubMed ID: 33212376
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
13. The potential of targeting Wnt/β-catenin in colon cancer.
Sebio A; Kahn M; Lenz HJ
Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
[TBL] [Abstract][Full Text] [Related]
14. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
16. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
17. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.
Xu X; Zhang M; Xu F; Jiang S
Mol Cancer; 2020 Nov; 19(1):165. PubMed ID: 33234169
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
Vallée A; Lecarpentier Y; Vallée JN
Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
[TBL] [Abstract][Full Text] [Related]
19. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
20. Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway.
Ouelaa-Benslama R; Emami S
Clin Res Hepatol Gastroenterol; 2011 Sep; 35(8-9):534-8. PubMed ID: 21782548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
